NLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on ...
MapLight has become the second Massachusetts-linked biotech to go public this year. The company sold 14.75 million shares at ...
Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of John Harrison as Clinical Vice President. As drug developers face growing demand for ...
Over the past generation, advances in treating common cancers—breast, lung, melanoma, and gastrointestinal (GI)—have improved ...
Zidovudine PBCA and MMA-SPM Emulsion polymerization and free-radical polymerization PBCA as a carrier; alcohol increases permeability of BMVECs to NPs [114] Indinavir Drug nanocrystals and lipoid E80 ...
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for ...
Comprehensive CNS-Focused Services The center provides end-to-end support including CNS-specific protocol design, regulatory ...
Dr. Barilero brings over 30 years of global regulatory leadership across CNS, neuropsychiatry, immuno-oncology, and rare diseases, with a proven track record in guiding Phase II–III programs, securing ...
Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development Technology Additional Predictive, Analytic and Descriptive ...
BofA rates Supernus Pharmaceuticals a buy, citing strong CNS drug growth and revenue boosts from acquisitions. Read more here ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback